Compare · DNTH vs NVO
DNTH vs NVO
Side-by-side comparison of Dianthus Therapeutics Inc. (DNTH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNTH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 41.3x DNTH ($4.44B).
- Over the past year, DNTH is up 347.3% and NVO is down 45.7% - DNTH leads by 393.0 points.
- DNTH has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- Dianthus Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $81.33+1.03%
- $41.01-4.51%
- Market cap
- $4.44B
- $183.15B
- 1M return
- -4.94%
- -10.44%
- 1Y return
- +347.33%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 12
- 8
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DNTH
- EVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics to Participate in Two Investor Conferences
- SEC Form 4 filed by Director Lawton Alison Frances
- SEC Form 4 filed by Director Romano Steven J.
- SEC Form 4 filed by Director Mcgeorge Anne
- SEC Form 4 filed by Director Read Simon
- SEC Form 4 filed by Director Violin Jonathan
- SEC Form 4 filed by Director Soteropoulos Paula
- SEC Form 4 filed by Director Kango Sujay
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care